Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.
Neehar Parikh, MD, medical director, Multidisciplinary Liver Tumor Clinic, medical director, Living Donor Liver Transplantation Program, assistant professor, University of Michigan Health, Michigan Medicine, discusses future research directions in hepatitis C-related hepatocellular carcinoma (HCC).
During the 2021 International Liver Cancer Association Annual Conference, findings from a retrospective cohort study were presented virtually. Moving forward, these analyses could be updated should additional systemic therapies get introduced to the HCC armamentarium to determine whether these agents induce a survival benefit in patients with hepatitis C-related HCC, Parikh says. However, this would be difficult to conduct prospectively at this point.
Additionally, hepatitis C is becoming an increasingly rare etiologic cause of HCC and cirrhosis because of improved screening and direct-acting antiviral therapies, Parikh explains.
Although less patients are presenting with viremic hepatitis C, this analysis serves to fulfill an unmet need. Additionally, it remains beneficial to explore other cohort studies to observe patients with active, treated hepatitis C-related HCC to determine how treatment affects outcomes, Parikh concludes.
Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology
Apalutamide/ADT Demonstrates 100% Biochemical RFS Rate in High-Risk Prostate Cancer
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer
2 Commerce Drive
Cranbury, NJ 08512